BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/24/2022 2:13:21 PM | Browse: 226 | Download: 812
 |
Received |
|
2021-10-19 00:34 |
|
Peer-Review Started |
|
2021-10-19 00:36 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-12-04 11:37 |
|
Revised |
|
2021-12-19 02:41 |
|
Second Decision |
|
2022-02-17 05:48 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-02-20 13:12 |
|
Articles in Press |
|
2022-02-20 13:12 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-02-14 03:55 |
|
Typeset the Manuscript |
|
2022-03-18 10:27 |
|
Publish the Manuscript Online |
|
2022-03-24 14:13 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ghada Abdelrahman Mohamed, Ehab Hasan Nashaat, Hadeer Mohamed Fawzy and Ahmed Mohamed ElGhandour |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ghada Abdelrahman Mohamed, MD, Lecturer, Department of Internal Medicine, Gastroenterology and Hepatology Unit, Faculty of Medicine, Ain Shams University, El Khalifa El-Maamon St., Abbassia, Cairo 11591, Egypt. ghadaabdelrahman@med.asu.edu.eg |
| Key Words |
Fibroblast growth factor 19; FGF-19; Fibroblast growth factors; Tumour biomarkers; Hepatocellular carcinoma; Detection; Cirrhosis |
| Core Tip |
We recruited 90 adult participants and divided them into three equal groups: Healthy controls, cirrhosis patients, and hepatocellular carcinoma (HCC) patients. We detected a high statistically significant difference in fibroblast growth factor 19 (FGF-19) levels among the three groups, with the highest level occurring in the HCC group, followed by the cirrhosis and control groups (236.44 ± 40.94 vs 125.63 ± 31.54 vs 69.60 ± 20.90 pg/mL, respectively, P ≤ 0.001). For the detection of HCC, receiver operating characteristic curve analysis showed that FGF-19 demonstrated a better diagnostic performance than alpha fetoprotein (area under the curve = 0.98 vs 0.78). Consequently, we can conclude that FGF-19 represents a possible novel non-invasive marker for HCC. |
| Publish Date |
2022-03-24 14:13 |
| Citation |
Mohamed GA, Nashaat EH, Fawzy HM, ElGhandour AM. Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma. World J Hepatol 2022; 14(3): 623-633 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i3/623.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i3.623 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
